Tsuji K, et al. - Authors attempted to elucidate the efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection among GT1-infected patients treated with LDV/SOF for 12 weeks. It was reported that the sustained virological response at 12 weeks post-treatment (SVR12) rate in patients with cirrhosis and NS5A RASs was 93.0% vs 100% in patients without cirrhosis or NS5A resistance-associated substitutions (RASs). Yielded data depicted that LDV/SOF therapy was highly effective and safe in elderly Japanese patients with HCV GT1, even in the presence of cirrhosis or NS5A RASs. It was deduced that subjects with SVR possibly presented with a lower risk of hepatocellular carcinoma.